OncoMatch/Clinical Trials/NCT07252232
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Is NCT07252232 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies daraxonrasib for pancreatic cancer.
Treatment: daraxonrasib — The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: KRAS mutation status documented
Documented RAS mutation status
Required: NRAS mutation status documented
Documented RAS mutation status
Required: HRAS mutation status documented
Documented RAS mutation status
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: multi-agent chemotherapy — perioperative (neoadjuvant, adjuvant, or both)
Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy
Cannot have received: direct RAS-targeted therapy
Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors)
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate kidney function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hartford Healthcare · Hartford, Connecticut
- Community Health Network · Indianapolis, Indiana
- Saint Luke's Cancer Institute · Kansas City, Missouri
- Taylor Cancer Research Center · Maumee, Ohio
- Avera Cancer Institute · Sioux Falls, South Dakota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify